Development of proprietary unique nM potent agonist of FPR/NOX2
for treatment of autoimmunity, inflammation and infections
ProNoxis is exploring a wide range of business development opportunities spanning the discovery and development process.
For our FPR/NOX2 project we are interested in entering co-development projects and sharing our proprietary small molecules with academic and industrial partners for collaboration and joint development.
Please contact us if you are interested in collaborating with Pronoxis and testing our small molecules in your models.